Willow Biosciences Inc.
CANSF
$0.0062
$0.0032106.67%
| Weiss Ratings | CANSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | CANSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CANSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.80 | |||
| Price History | CANSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 26.53% | |||
| 30-Day Total Return | -69.76% | |||
| 60-Day Total Return | -88.08% | |||
| 90-Day Total Return | -90.08% | |||
| Year to Date Total Return | -84.69% | |||
| 1-Year Total Return | -90.43% | |||
| 2-Year Total Return | -91.18% | |||
| 3-Year Total Return | -97.66% | |||
| 5-Year Total Return | -98.16% | |||
| 52-Week High % Change | -93.76% | |||
| 52-Week Low % Change | 108.00% | |||
| Price | CANSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.10 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Apr 09, 2025 | |||
| 52-Week High Price (Date) | Jul 12, 2024 | |||
| Valuation | CANSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 510.89K | |||
| Enterprise Value | 1.65M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.03 | |||
| Earnings Per Share Growth | -55.53% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.26 | |||
| Price/Book (Q) | -2.60 | |||
| Enterprise Value/Revenue (TTM) | 0.49 | |||
| Price | $0.01 | |||
| Enterprise Value/EBITDA (TTM) | -0.48 | |||
| Enterprise Value/EBIT | -0.40 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | CANSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 142.33M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CANSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 403 910 5140 | |||
| Address | 202, 1201-5th Street SW Calgary, AB T2R 0Y6 | |||
| Website | www.willowbio.com | |||
| Country | Canada | |||
| Year Founded | 2019 | |||
| Profitability | CANSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -121.19% | |||
| Profit Margin | -134.20% | |||
| Management Effectiveness | CANSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -75.51% | |||
| Return on Equity | -- | |||
| Income Statement | CANSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 3.38M | |||
| Total Revenue (TTM) | 3.38M | |||
| Revenue Per Share | $0.02 | |||
| Gross Profit (TTM) | 3.72M | |||
| EBITDA (TTM) | -3.47M | |||
| EBIT (TTM) | -4.10M | |||
| Net Income (TTM) | -4.54M | |||
| Net Income Avl. to Common (TTM) | -4.54M | |||
| Total Revenue Growth (Q YOY) | 1,955.66% | |||
| Earnings Growth (Q YOY) | 64.00% | |||
| EPS Diluted (TTM) | -0.03 | |||
| EPS Diluted Growth (Q YOY) | 68.53% | |||
| Balance Sheet | CANSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 635.90K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 456.60K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -351.00K | |||
| Current Ratio (Q) | 0.330 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 1.73M | |||
| Total Current Liabilities (Q) | 1.39M | |||
| Total Debt (Q) | 1.37M | |||
| Total Liabilities (Q) | 2.08M | |||
| Total Common Equity (Q) | -351.00K | |||
| Cash Flow | CANSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 57.30K | |||
| Cash from Financing (TTM) | 581.30K | |||
| Net Change in Cash (TTM) | -2.06M | |||
| Levered Free Cash Flow (TTM) | -1.42M | |||
| Cash from Operations (TTM) | -2.74M | |||
